drugset / Trial / NCT03695094

A Study in Participants With Epilepsy, to Evaluate the Pharmacokinetics, Safety and Tolerability of Oxcarbazepine on Padsevonil

NCT03695094

Phase 1 Completed 31 enrolled UCB Biopharma S.P.R.L.
Non-randomizedParallel-groupOpen-labelBasic science

Summary

The purpose of the study is to evaluate the effect of stable coadministered oxcarbazepine (OXC), on the pharmacokinetics (PK), safety, tolerability of padsevonil (PSL) and the plasma PK of PSL metabolites, UCB1431322-000 and UCB1447499-000, in study participants with epilepsy compared with study participants co-medicated with stable doses of levetiracetam (LEV), lamotrigine (LTG) or brivaracetam (BRV) therapy.

Timeline

Start
2018-09-18
Primary completion
2019-05-18
Completion
2019-05-30

Drugs

EvaluationDrugModalityDoseRoute
Subject Brivaracetam Small molecule
Subject Lamotrigine Small molecule
Subject Levetiracetam Other / unclassified
Subject Oxcarbazepine Small molecule
Subject Padsevonil Small molecule

Indications